Search / Trial NCT00001818

Combination Drug Treatment of Pediatric HIV Infection

Launched by NATIONAL CANCER INSTITUTE (NCI) · May 21, 2002

Apply for Trial

Trial Information

Current as of June 14, 2024

Completed

Keywords

Antiretrovirals Resistant Virus T Cell Activation Immune Suppression Cytotoxic Agent

Description

This is a pilot study to determine the safety, toxicity, virologic and immunologic effects of combination therapy with hydroxyurea, a cytostatic chemotherapeutic agent, two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor in children with HIV infection. We will enroll HIV-infected children who have detectable viral loads (greater than 10,000 copies/ml). Patients will be stratified upon enrollment by CD4 cell count (less than or greater than 200 CD4 cells/mm(3)). Two dose levels of hydroxyurea will be utilized (7.5 mg/kg/dose twice daily and 12...

Gender

All

Eligibility criteria

  • Patients must have a diagnosis of HIV-1 infection as defined by the Centers for Disease Control.
  • All patients must have availability of a parent or legal guardian able and willing to give informed consent and comply with the requirements of the study.
  • Post menarchal adolescent females must have a negative urine pregnancy test within 14 days prior to initiation of study therapy and consent to urine pregnancy testing at every visit for the remainder of the study. If sexually active, must also be willing to use a barrier method of contraception or willing to remain sexually abstinent during the course of the study.
  • Sexually active males must agree to practice barrier contraception for the duration of the study.
  • Patients must have a plasma HIV-RNA viral load of greater than or equal to 10,000 copies/ml (4.0 log10) on 2 occasions at least 1 week apart at study entry.
  • Patients must be between the ages of 3 years to 21 years old and able to swallow capsules.
  • Patients must have an age-adjusted normal serum creatinine or a creatinine clearance greater than or equal to 60 ml/min/1.73 m(2).
  • Patients must have an absolute granulocyte count greater than 1,500/mm(3), hemoglobin greater than 8 gm/dL, and platelet count greater than 75,000/mm(3).
  • Patients must have an SGOT/SGPT/GGT less than 2.5 times normal unless considered to be attributable to underlying HIV disease.
  • Patients must have a serum amylase less than 1.5 times the upper limit of normal. If abnormal, a fractionated pancreatic amylase less than 45 U/L.
  • Immunomodulating agents such as corticosteroids for LIP, IVIG, erythropoietin, and anti-D will be allowed.
  • Must not be critically ill or clinically unstable.
  • Must not have a history or a prior malignancy requiring active treatment within the last 2 years.
  • Must not have a prior history of hydroxyurea use.
  • Must not have the presence of an active infection requiring acute intervention at the time of entry.
  • Patients receiving treatment for an infection that requires prolonged treatment must have been stable on therapy for at least 7 days prior to study entry.
  • Prophylaxis for PCP as well as maintenance anti-mycobacterial therapy, antifungal, and anti-viral therapy at the time of study will be allowed.
  • Must not currently use G-CSF or GM-CSF to maintain an adequate neutrophil count.
  • No evidence of active peripheral neuropathy.
  • No history of peripheral neuropathy of Grade III or greater severity associated with the use of antiretroviral agents.
  • No patients with a previous history of pancreatitis attributed to ddI.
  • No previous history of pancreatitis requiring total parental nutrition within 2 years of study enrollment.
  • Patients will be excluded if unable to tolerate antiretroviral therapy with stavudine, didanosine or efavirenz due to allergic symptoms felt to be related to these antiretroviral therapeutic agents.
  • Patients must not have a history of erythema multiforme or Stevens Johnson Syndrome attributable to stauvudine, didanosine or nonnucleoside RTI.
  • No patients with multiple circumscribed active retinal lesions characterized by alterations in retinal pigmentary epithelium consistent with didanosine toxicity.
  • No antiretroviral therapy within two weeks of study entry.

Attachments

readout_NCT00001818_2024-06-14.pdf

4.5 MB

NCT00001818_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0